Table 2.
Intraoperative and postoperative details
| Parameters | Case 1 | Case 2 | Case 3 | Case 4 |
|---|---|---|---|---|
| Operation time (min) | 480 | 600 | 600 | 570 |
| Blood loss (mL) | 150 | 230 | 270 | 260 |
| Blood transfusion | No | No | No | No |
| Conversion to OPD | No | No | No | No |
| Size of the mass (cm) | 2.0 | 4.5 | 3.0 | 3.0 |
| ICU stay (days) | 1 | 1 | 1 | 1 |
| Postoperative analgesia | No | No | No | No |
| Able to stand and walk without assistance (days) | 3 | 2 | 3 | 4 |
| Time to first passage of flatus (days) | 4 | 3 | 2 | 3 |
| Time to oral intake (days) | 7 | 5 | 5 | 6 |
| Postoperative hospital stay (days) | 9 | 12 | 11 | 8 |
| Complications | No | No | No | No |
| Final pathologic results | Duodenal papilla inflammatory mass | Pancreatic serous cystic neoplasm | Pancreatic ductal adenocarcinoma T3N1M0 (IIB) | Glucagonoma (NET G2) at the pancreatic head with serous cystic neoplasm at the body and tail |
| 30-day readmission | No | No | No | No |
| 30-day mortality | No | No | No | No |
OPD open pancreaticoduodenectomy, ICU intensive care unit, T3N1M0 (IIB) TNM staging and clinical staging were based on AJCC/UICC Staging Manual, Seventh Edition, (NET G2) the tumor was classified according to the WHO 2010 classification system for pancreatic endocrine tumors (PETs)